Optic tract hyperintensity on T2-weighted images among patients with pituitary macroadenoma: correlation with visual impairment

Patient No./Age (y)/SexDurationSize (mm)OCASVADVFDPathologyIAT
1/36/M2 mo18+
2/61/M9 y23.7++ (rt 0.7, lt blind)+PA
3/42/F16 mo26.5++++ (rt 0.02, lt 1.5)+PA (corticotro)
4/38/F10 mo14+
5/40/M6 mo35++++ (rt 0.07, lt 0.05)+PA (null)
6/55/F4 y46++++ (rt 0.06, lt 0.06)+PA (chromophobe)
7/65/F2 mo13+PA (null)
8/74/M18 mo16.4+++ (rt 0.7, lt 0.4)+PA (null)
9/54/F3 mo27+++ (rt 0.06, lt 0.1)+PA (nonfunctioning)+ (rt 1.2, lt 0.8)
10/65/M2 mo13++ (rt light sense)+Pituitary carcinoma
11/59/F14 mo35++++ (rt 0.3, lt 0.9)+PA (null)
12/55/M3 mo22++++ (rt 0.5, lt 0.1)+PA+ (rt 1.0, lt 1.0)
13/41/F19 mo25++++ (hand sense)+PA (null)
14/37/F3 mo16+
15/70/F6 mo18+++ (rt 0.1, lt blind)
16/27/M6 mo15++ (finger sense)+PA (chromophobe)+ (rt 0.7, lt 0.9)
17/58/M26 mo24++++ (rt 1.5, lt 0.4)PA (null)
18/21/F8 mo30++PA (GH)
19/50/F10 y51++++ (rt 0.03, lt 0.1)+PA(FSH-LH)
20/74/F1.5 mo18++ (lt light sense)PA (prolactinoma)+ (rt 0.8, lt 0.4)
21/66/F2 mo15PA (null)
22/63/M2 mo23.7++++ (rt 0.1, lt 0.7)+PA (chromophobe)+ (rt 0.7, lt 0.8)
23/54/F3 mo13PA
24/56/F3 mo20PA
25/45/M2 mo16+PA (chromophobe)
26/36/M2 mo12.2
27/50/M3 mo16++++ (rt 0.9, lt 0.3)+PA (GH)+ (rt 0.9, lt 0.7)
  • Note.—OC indicates optic chiasm compression; AS, abnormal signal in optic nerve; VAD, visual acuity disturbance; VFD, visual field disturbance; IAT, improvement of visual acuity after treatment; PA, pituitary adenoma; FSH-LH, follicle stimulating hormone-luteinizing hormone; GH, growth hormone.